Autolus Therapeutics PLC Stock Rises on AUCATZYL Launch Announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 08 2024
0mins
Should l Buy AUTL?
Autolus Therapeutics PLC has seen a significant increase in its stock price, rising by 11.29% following the announcement of the launch of AUCATZYL for the treatment of relapsed B-cell leukemia in the NHS. This new treatment option is expected to greatly enhance accessibility for patients in England and Wales, addressing an urgent need for innovative therapies in the biopharmaceutical market.
The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL for use in adult patients, which is a major step forward for Autolus. The approval is based on positive results from the FELIX study, which demonstrated the drug's efficacy in treating this challenging condition. This development not only strengthens Autolus's competitive position but also reflects the company's commitment to improving patient outcomes.
Investors are optimistic about the potential impact of AUCATZYL on Autolus's revenue and market share, as the company prepares for an imminent launch. The emphasis on patient involvement during the NICE evaluation process has also enhanced Autolus's reputation within the patient community, further solidifying its brand image.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AUTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AUTL
Wall Street analysts forecast AUTL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.480
Low
5.00
Averages
7.18
High
10.00
Current: 1.480
Low
5.00
Averages
7.18
High
10.00
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Asgard Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Asgard Therapeutics has appointed Wolfram Brugger as Chief Medical Officer, marking a pivotal advancement for the company as it progresses its personalized cancer immunotherapy platform toward clinical development, with Brugger expected to lead clinical strategy, regulatory engagement, and trial execution.
- Extensive Clinical Experience: Brugger has been involved in over 130 Phase I-III clinical oncology trials across various cancer types, including solid tumors, providing invaluable experience and guidance for Asgard's clinical development efforts.
- Clinical Development Readiness: This appointment comes at a crucial time as Asgard Therapeutics prepares for clinical entry, and Brugger's expertise is expected to facilitate the company's success in regulatory and trial execution.
- Revenue Target Reaffirmation: Asgard Therapeutics reaffirms its revenue target of $120M to $135M for AUCATZYL by 2026 while expanding its pivotal trial pipeline, demonstrating the company's confidence in future growth.
See More
Autolus Therapeutics to Participate in Investor Conferences
- Investor Conference Schedule: Autolus Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, where CEO Dr. Christian Itin will present at 10:15 AM EDT, likely attracting investor interest and enhancing the company's visibility.
- Webcast Availability: The presentation will be available via a webcast on the company's website under the 'Investor Relations & Media' section, with a replay accessible for 90 days post-event, which will help broaden the investor base and improve transparency.
- Investor Meeting Location: The company will also host investor meetings in Amsterdam on April 16, 2026, allowing management to engage directly with potential investors, aimed at strengthening investor relations and facilitating future funding opportunities.
- Company Background Overview: Autolus Therapeutics is a commercial-stage biopharmaceutical company focused on developing and manufacturing next-generation T cell therapies, with its marketed product AUCATZYL® and a pipeline targeting hematological malignancies and autoimmune diseases, indicating strong market potential.
See More
Autolus Therapeutics Reports Strong 2025 Earnings with AUCATZYL Launch Success
- AUCATZYL Sales Performance: Autolus Therapeutics achieved $74.3 million in AUCATZYL sales for 2025, marking a successful U.S. launch with 67 centers activated by year-end, indicating strong market demand and positive physician feedback.
- 2026 Financial Outlook: Management reiterated guidance for 2026 net revenue between $120 million and $135 million, expecting a shift to positive gross margins and activation of over 80 centers by year-end, reflecting confidence in future growth.
- Clinical Data Support: The ROCCA Consortium reported a 92% overall complete remission rate at day 28 for 91 patients treated with AUCATZYL, closely aligning with prior clinical trial data, which further bolsters physician confidence and market acceptance.
- R&D and Financial Status: Q4 2025 net product revenue was $23.3 million, with R&D expenses at $35.6 million; despite an operating loss of $72.5 million, the company maintains $300.7 million in cash and equivalents, sufficient to fund operations into Q4 2027.
See More
AUCATZYL® 2025 Financial Results and Market Outlook
- Revenue Growth: AUCATZYL® reported net product revenue of $23.3 million for Q4 2025 and $74.3 million for the full year, indicating strong demand in the U.S. market, which is expected to drive future revenue growth for Autolus.
- UK Market Launch: Following a successful evaluation by the National Institute for Health and Care Excellence (NICE), AUCATZYL® was launched in the UK in January 2026, marking a significant step in the company's international expansion strategy and is anticipated to further enhance market share.
- Positive Outlook: Autolus projects net product revenue for AUCATZYL® to range between $120 million and $135 million in 2026, with expectations of achieving a positive gross margin, reflecting positive changes in operational efficiency and market demand.
- Clinical Trial Progress: AUCATZYL® has demonstrated a favorable safety and efficacy profile in multiple clinical trials, particularly in pediatric patients with relapsed/refractory B-ALL, where preliminary data shows an overall response rate of 95.5%, laying a solid foundation for future market promotion.
See More
Autolus Therapeutics Q4 Earnings Report Analysis
- Disappointing Earnings: Autolus Therapeutics reported a Q4 GAAP EPS of -$0.34, missing expectations by $0.07, indicating challenges in profitability that may affect investor confidence.
- Revenue Beat: Despite the EPS miss, Q4 revenue reached $24.29 million, exceeding market expectations by $0.37 million, suggesting that the company still possesses some growth potential in sales.
- Cautious Future Outlook: As FY 2025 earnings approach, market expectations regarding Autolus's profitability and revenue growth will be closely monitored, requiring investors to assess the company's positioning in the competitive biopharmaceutical market.
- Analyst Rating Dynamics: Seeking Alpha's Quant Rating on Autolus Therapeutics reflects market divergence regarding its future performance, highlighting differing investor perspectives on the company's long-term strategy and financial health.
See More
Autolus Therapeutics Earnings Announcement Scheduled
- Earnings Release Date: Autolus Therapeutics is set to announce its FY earnings on March 27 before market open, with investors keenly awaiting performance insights to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.43, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability, albeit still facing losses.
- Significant Revenue Growth: The consensus revenue estimate is $74.75 million, representing a substantial year-over-year increase of 638.6%, showcasing the company's strong performance in market demand and product sales.
- Performance Revision Insights: Over the past year, Autolus has only beaten EPS estimates 25% of the time, with no revenue estimates surpassed, highlighting market uncertainty regarding its profitability trajectory.
See More
Asgard Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Asgard Therapeutics has appointed Wolfram Brugger as Chief Medical Officer, marking a pivotal advancement for the company as it progresses its personalized cancer immunotherapy platform toward clinical development, with Brugger expected to lead clinical strategy, regulatory engagement, and trial execution.
- Extensive Clinical Experience: Brugger has been involved in over 130 Phase I-III clinical oncology trials across various cancer types, including solid tumors, providing invaluable experience and guidance for Asgard's clinical development efforts.
- Clinical Development Readiness: This appointment comes at a crucial time as Asgard Therapeutics prepares for clinical entry, and Brugger's expertise is expected to facilitate the company's success in regulatory and trial execution.
- Revenue Target Reaffirmation: Asgard Therapeutics reaffirms its revenue target of $120M to $135M for AUCATZYL by 2026 while expanding its pivotal trial pipeline, demonstrating the company's confidence in future growth.
See More
Autolus Therapeutics to Participate in Investor Conferences
- Investor Conference Schedule: Autolus Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, where CEO Dr. Christian Itin will present at 10:15 AM EDT, likely attracting investor interest and enhancing the company's visibility.
- Webcast Availability: The presentation will be available via a webcast on the company's website under the 'Investor Relations & Media' section, with a replay accessible for 90 days post-event, which will help broaden the investor base and improve transparency.
- Investor Meeting Location: The company will also host investor meetings in Amsterdam on April 16, 2026, allowing management to engage directly with potential investors, aimed at strengthening investor relations and facilitating future funding opportunities.
- Company Background Overview: Autolus Therapeutics is a commercial-stage biopharmaceutical company focused on developing and manufacturing next-generation T cell therapies, with its marketed product AUCATZYL® and a pipeline targeting hematological malignancies and autoimmune diseases, indicating strong market potential.
See More
Autolus Therapeutics Reports Strong 2025 Earnings with AUCATZYL Launch Success
- AUCATZYL Sales Performance: Autolus Therapeutics achieved $74.3 million in AUCATZYL sales for 2025, marking a successful U.S. launch with 67 centers activated by year-end, indicating strong market demand and positive physician feedback.
- 2026 Financial Outlook: Management reiterated guidance for 2026 net revenue between $120 million and $135 million, expecting a shift to positive gross margins and activation of over 80 centers by year-end, reflecting confidence in future growth.
- Clinical Data Support: The ROCCA Consortium reported a 92% overall complete remission rate at day 28 for 91 patients treated with AUCATZYL, closely aligning with prior clinical trial data, which further bolsters physician confidence and market acceptance.
- R&D and Financial Status: Q4 2025 net product revenue was $23.3 million, with R&D expenses at $35.6 million; despite an operating loss of $72.5 million, the company maintains $300.7 million in cash and equivalents, sufficient to fund operations into Q4 2027.
See More
AUCATZYL® 2025 Financial Results and Market Outlook
- Revenue Growth: AUCATZYL® reported net product revenue of $23.3 million for Q4 2025 and $74.3 million for the full year, indicating strong demand in the U.S. market, which is expected to drive future revenue growth for Autolus.
- UK Market Launch: Following a successful evaluation by the National Institute for Health and Care Excellence (NICE), AUCATZYL® was launched in the UK in January 2026, marking a significant step in the company's international expansion strategy and is anticipated to further enhance market share.
- Positive Outlook: Autolus projects net product revenue for AUCATZYL® to range between $120 million and $135 million in 2026, with expectations of achieving a positive gross margin, reflecting positive changes in operational efficiency and market demand.
- Clinical Trial Progress: AUCATZYL® has demonstrated a favorable safety and efficacy profile in multiple clinical trials, particularly in pediatric patients with relapsed/refractory B-ALL, where preliminary data shows an overall response rate of 95.5%, laying a solid foundation for future market promotion.
See More
Autolus Therapeutics Q4 Earnings Report Analysis
- Disappointing Earnings: Autolus Therapeutics reported a Q4 GAAP EPS of -$0.34, missing expectations by $0.07, indicating challenges in profitability that may affect investor confidence.
- Revenue Beat: Despite the EPS miss, Q4 revenue reached $24.29 million, exceeding market expectations by $0.37 million, suggesting that the company still possesses some growth potential in sales.
- Cautious Future Outlook: As FY 2025 earnings approach, market expectations regarding Autolus's profitability and revenue growth will be closely monitored, requiring investors to assess the company's positioning in the competitive biopharmaceutical market.
- Analyst Rating Dynamics: Seeking Alpha's Quant Rating on Autolus Therapeutics reflects market divergence regarding its future performance, highlighting differing investor perspectives on the company's long-term strategy and financial health.
See More
Autolus Therapeutics Earnings Announcement Scheduled
- Earnings Release Date: Autolus Therapeutics is set to announce its FY earnings on March 27 before market open, with investors keenly awaiting performance insights to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.43, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability, albeit still facing losses.
- Significant Revenue Growth: The consensus revenue estimate is $74.75 million, representing a substantial year-over-year increase of 638.6%, showcasing the company's strong performance in market demand and product sales.
- Performance Revision Insights: Over the past year, Autolus has only beaten EPS estimates 25% of the time, with no revenue estimates surpassed, highlighting market uncertainty regarding its profitability trajectory.
See More
